Eledon Pharmaceuticals (ELDN) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and market opportunity

• Focuses on anti-CD40 ligand therapy to prevent organ transplant rejection, with lead asset tegoprubart advanced since 2020.

• Conducts three kidney transplant trials (phase 1b, phase 2, and long-term extension) and a phase 2 islet cell transplant study.

• Kidney transplantation is the largest segment, with about 27,000 procedures annually in the U.S. and a concentrated market of 200-250 centers.

• Current standard of care, tacrolimus, remains a multi-billion dollar product despite significant toxicities.

• Tegoprubart aims to replace tacrolimus, addressing its nephrotoxicity, diabetogenic effects, and other side effects.

Clinical development and upcoming milestones

• Phase 1b kidney transplant study showed eGFR improvements of 30%-90% over historical controls; next update expected mid-next year.

• Phase 2 kidney transplant trial (120 patients) completed enrollment ahead of schedule; data readout expected Q4 next year.

• Islet cell transplant phase 2 enrolling as planned, targeting high-risk Type 1 diabetes; full data on nine patients expected in about a year.

• Both kidney and islet cell programs will inform potential phase 3 discussions with the FDA if data are positive.

• Sufficient capital raised to fund operations through end of 2026, with key data readouts and preclinical updates expected in the next 12 months.

Competitive landscape and differentiation

• Competing anti-CD40 ligand programs from Sanofi, Biogen/UCB, and Amgen target broader autoimmune indications, not transplant.

• Tegoprubart and Sanofi's antibody share similar IgG1 structure with modified Fc function; Biogen/UCB and Amgen use different formats.

• Tegoprubart demonstrates longer half-life and no observed antidrug antibodies compared to competitors.

• Initial administration will be IV every three weeks, with subcutaneous formulation developed but not required for transplant patients.

• Transplant viewed as a niche but lucrative market, suitable for a focused commercial approach.